Altimmune, Inc. (ALT) vs Phathom Pharmaceuticals, Inc. (PHAT)
A side-by-side comparison of Altimmune, Inc. and Phathom Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ALT
Altimmune, Inc.
$2.67HealthcareDelayed quote: Oct 6, 2026, 12:20 PM EDT
PHAT
Phathom Pharmaceuticals, Inc.
$6.68HealthcareDelayed quote: Oct 6, 2026, 12:15 PM EDT
Total return — ALT vs PHAT
growth of $100 · dividends reinvested · last 7yALT +32.2% (+4.1%/yr)PHAT -72.8% (-17.0%/yr)ALT compounded faster over this window
ALT PHAT
ALT vs PHAT: by the numbers
- •PHAT is the larger company ($540M vs $519M market cap).
- •Both run net losses; PHAT's is the smaller (-41.34% vs -296000.00% net margin).
Metrics side by side
Valuation
| Metric | ALT | PHAT |
|---|---|---|
| P/S ratio | 16749.86 | 2.25 |
| P/B ratio | 1.09 | N/A |
Profitability
| Metric | ALT | PHAT |
|---|---|---|
| Gross margin | 100.00% | 82.92% |
| Operating margin | -230460.98% | -91.36% |
| Net margin | -296000.00% | -41.34% |
| ROE | -19.35% | N/A |
| ROIC | -19.47% | -23.45% |
Growth (annualized)
| Metric | ALT | PHAT |
|---|---|---|
| Revenue CAGR (5Y) | -65.38% | N/A |
| Total return CAGR (5Y) | -25.30% | -26.93% |
Frequently asked
- How have ALT and PHAT total returns compared?
- Over the past 5 years, ALT delivered -25.30% and PHAT delivered -26.93% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.